VEGFA and Polypoidal choroidal vasculopathy: In the present study, we investigated the short-term outcomes of aflibercept 8 mg, the most recently introduced second-generation VEGF inhibitor, in eyes with polypoidal choroidal vasculopathy (PCV) and compared the results with those of brolucizumab.